» Articles » PMID: 12865438

Vascular Endothelial Growth Factor Receptor-1 is Deposited in the Extracellular Matrix by Endothelial Cells and is a Ligand for the Alpha 5 Beta 1 Integrin

Overview
Journal J Cell Sci
Specialty Cell Biology
Date 2003 Jul 17
PMID 12865438
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase receptor for several growth factors of the VEGF family. Endothelial cells express a membrane-spanning form of VEGFR-1 and secrete a soluble variant of the receptor comprising only the extracellular region. The role of this variant has not yet been completely defined. In this study, we report that the secreted VEGFR-1 is present within the extracellular matrix deposited by endothelial cells in culture, suggesting a possible involvement in endothelial cell adhesion and migration. In adhesion assays, VEGFR-1 extracellular region specifically promoted endothelial cell attachment. VEGFR-1-mediated cell adhesion was divalent cation-dependent, and inhibited by antibodies directed against the alpha 5 beta 1 integrin. Moreover, VEGFR-1 promoted endothelial cell migration, and this effect was inhibited by anti-alpha 5 beta 1 antibodies. Direct binding of VEGFR-1 to the alpha 5 beta 1 integrin was also detected. Finally, binding to VEGFR-1 initiated endothelial cell spreading. Altogether these results indicate that the soluble VEGFR-1 secreted by endothelial cells becomes a matrix-associated protein that is able to interact with the alpha 5 beta 1 integrin, suggesting a new role of VEGFR-1 in angiogenesis, in addition to growth factor binding.

Citing Articles

Mechanistic computational modeling of sFLT1 secretion dynamics.

Gill A, Kinghorn K, Bautch V, Mac Gabhann F bioRxiv. 2025; .

PMID: 40027776 PMC: 11870409. DOI: 10.1101/2025.02.12.637983.


Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?.

Failla C, Carbone M, Ramondino C, Bruni E, Orecchia A Biomedicines. 2025; 13(1).

PMID: 39857591 PMC: 11763294. DOI: 10.3390/biomedicines13010006.


Soluble FLT-1 in angiogenesis: pathophysiological roles and therapeutic implications.

Wazan L, Widhibrata A, Liu G Angiogenesis. 2024; 27(4):641-661.

PMID: 39207600 DOI: 10.1007/s10456-024-09942-8.


Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide.

Flies C, Friedrich M, Lohmann P, van Garderen K, Smits M, Tonn J Neuro Oncol. 2024; 26(5):902-910.

PMID: 38219019 PMC: 11066942. DOI: 10.1093/neuonc/noad247.


Targeting integrin α5β1 in urological tumors: opportunities and challenges.

Zhou X, Zhu H, Luo C, Xiao H, Zou X, Zou J Front Oncol. 2023; 13:1165073.

PMID: 37483505 PMC: 10358839. DOI: 10.3389/fonc.2023.1165073.